Natera, Inc. (NTRA)财务
NASDAQ · Healthcare · Medical - Diagnostics & Research · 员工6,138人 · CEO Steven Leonard Chapman
- 股价
- $414.30 -4.98%
- 市值
- $597亿
- 企业价值
- $589亿
- 最近财报
- Q2 '26 2026-08-07提交
- 下次财报
- 2026-11-05 EPS预期 -$0.28
营收(TTM)$27.1亿+37.8% 对比去年同期最近4个季度;柱状图=各季度
营业利润率(TTM)-10.7%+4.2 百分点 对比去年同期营业利润 -$2.9亿
净利润(TTM)-$1.92亿+24.0% 对比去年同期税后,含营业外收益
自由现金流(TTM)$7170万-31.4% 对比去年同期资本支出 $1.57亿
稀释EPS(TTM)-$1.36+28.8% 对比去年同期最近4个季度之和
净现金$8.53亿+4.0% 对比去年同期现金 + 短期投资 - 债务
估值与关键数据
- 市值
- $597亿 EV $589亿
- 营收
- $27.1亿 过去12个月
- 营收增速
- +26% FY2026年一致预期
- 净利润率
- -7.1% 净利润 / 营收,TTM
- P/E
- -304.6× 预期 -284.9×(FY2026)
- P/S
- 22.1× 股价 / 营收,TTM
- EV / EBITDA
- -329.4× TTM
- 自由现金流
- $7170万 过去12个月
- 净利润
- -$1.92亿 过去12个月
- 营收预期
- $29.1亿 FY2026年一致预期
- 盈利
- 2026-11-05 营收预期 $7.08亿
- 股息
- – 无股息
核心要点
根据披露数据计算,每条结论都附有其依据的数字。
- 最近财报(2026-08-06):营收超预期13.8%,EPS 超预期4.8%营收$7.53亿,预期$6.61亿(+13.8%);EPS -$0.47,预期-$0.49(+4.8%)。
- 营收增长加速:同比37.7%Q2 '26营收$7.53亿,此前四个季度的平均值为36.4%。
- 营业利润率-10.7%(TTM),较去年同期+4.2 百分点营收增长37.8%,营业利润增长1.3%。
- 资本支出占营收的5.8%(去年为4.2%)最近4个季度投入$1.57亿(同比+90.6%)。自由现金流$7170万。
- 稀释股数一年内增加5.1%Q2 '26稀释股数1.43亿,一年前为1.36亿。
- 净现金 $8.53亿现金 + 短期投资 $10.9亿,含租赁债务 $2.38亿;一年前净现金 $8.2亿。
上一季度:Q2 '26
截至2026-06-30的季度。与去年同期及财报发布前的分析师一致预期对比。
本季度与去年同期
| Q2 '26 | 去年同期 | 变化 | |
|---|---|---|---|
| 营收 | $7.53亿 | $5.47亿 | +37.7% |
| 毛利率 | 64.5% | 63.5% | +1.0 百分点 |
| 营业利润 | -$7580万 | -$1.1亿 | +31.3% |
| 营业利润率 | -10.1% | -20.2% | +10.1 百分点 |
| 净利润 | -$6700万 | -$1.01亿 | +33.7% |
| 稀释EPS | -$0.47 | -$0.74 | +36.5% |
| 经营现金流 | $5480万 | $3760万 | +45.8% |
| 资本支出 | $6340万 | $2590万 | +144.9% |
| 自由现金流 | -$864万 | $1170万 | -174.0% |
| R&D | $2.28亿 | $1.46亿 | +55.8% |
| 股权激励费用 | $1.03亿 | $9340万 | +10.4% |
实际 vs 一致预期
2026-08-06| 实际 | 一致预期 | 对比预期 | |
|---|---|---|---|
| 营收 | $7.53亿 | $6.61亿 | +13.8% |
| EPS(一致预期口径) | -$0.47 | -$0.49 | +4.8% |
来自2026-08-06发布的Q2 '26财报：营收及分析师预期口径的EPS（通常为调整后），可能与上方报表中的EPS不同。
EPS与一致预期
最近8次财报营收
收入从何而来,按业务线和地区逐季展示。
营收、营业利润与增速
季度按业务线划分的营收
堆叠,季度| 分部 | Q2 '26 | 同比 | 占比 | TTM | TTM同比 | 12个季度 |
|---|---|---|---|---|---|---|
| Product | $7.48亿 | +37.4% | 100.0% | $26.9亿 | +13.9% | |
| Licensing and other | – | – | – | – | – | |
| Oncology | $30万 | – | 0.0% | – | – |
按地区划分的营收
占总额比例| 分部 | Q2 '26 | 同比 | 占比 | TTM | TTM同比 | 12个季度 |
|---|---|---|---|---|---|---|
| United States | $7.39亿 | – | 98.2% | – | – | |
| United States | – | – | – | – | – | |
| EMEA | $902万 | – | 1.2% | – | – | |
| Europe, Middle East, India, Africa | – | – | – | – | – | |
| Americas, excluding U.S. | – | – | – | – | – | |
| Asia Pacific and Other | – | – | – | – | – | |
| Americas, Excluding United States | $222万 | – | 0.3% | – | – | |
| Asia Pacific And Other | $205万 | – | 0.3% | – | – |
利润率与成本结构
每一单位营收在各层级还剩多少,成本又花在哪里。
利润率
季度成本占营收比例
季度现金流与资本配置
创造了多少现金,用在何处,又有多少回到股东手中。
经营现金流、资本支出、自由现金流
季度现金用途与经营现金流
财年最近4个季度
现金流量表- 经营现金流
- $2.28亿
- 资本支出
- -$1.57亿
- 股票回购
- $0
- 股息
- $0
- 收购
- -$1600万
- 债务净发行
- $0
- 股权激励费用
- $3.81亿
- 自由现金流
- $7170万
- 股东回报 / FCF
- -0.0%
股数与EPS
季度,稀释资产负债表
各季度末的流动性、投资和债务。
现金、投资与债务
季度末估值与回报
当前估值倍数与公司自身过去五个财年对比;分析师目标价与评级。
估值倍数与回报
TTM与过去5个财年| 当前 | 5年均值 | 当前处于5年区间的位置 | |
|---|---|---|---|
| P/E(TTM) | -304.6× | – | – |
| EV / EBITDA | -329.4× | – | – |
| EV / 营收 | 21.7× | 9.9× | 4.8× – 14.0× |
| 股价 / FCF | 832.9× | 286.1× 5年中的2年 | 285.1× – 287.1× |
| 股价 / 净资产 | 32.6× | 12.6× | 5.6× – 18.3× |
| FCF收益率 | 0.1% | -4.0% | -12.1% – 0.4% |
| 投入资本回报率 | -10.0% | -30.6% | -46.2% – -11.1% |
| 净资产收益率 | -11.7% | -46.9% | -77.6% – -12.2% |
分析师
一致目标价 $386.00 (-6.8%)
区间 $245.00 – $500.00 · 评级 Buy
强烈买入0
买入25
持有3
卖出0
强烈卖出0
展望
分析师对未来财年的一致预期,以及按当前股价意味着什么。
一致预期
| 财年 | 营收 | 增速 | EPS | 增速 | 按当前股价的P/E | 分析师(EPS) |
|---|---|---|---|---|---|---|
| FY2026 | $29.1亿 | +26.2% | -$1.45 | +4.3% | -284.9× | 13 |
| FY2027 | $35.2亿 | +20.9% | -$0.37 | +74.6% | -1,122.2× | 12 |
| FY2028 | $42.6亿 | +21.1% | $1.27 | +445.3% | 325.0× | 16 |
| FY2029 | $51.3亿 | +20.5% | $2.14 | +68.1% | 193.3× | 13 |
| FY2030 | $61.9亿 | +20.5% | $3.65 | +70.2% | 113.6× | 13 |
财务报表
利润表、资产负债表和现金流量表的每一项,含12个季度和10个财年,以金额、占营收比例或增速展示。
全部披露项目
Natera, Inc.在近期10-Q / 10-K文件中标记的全部235项数据,附SEC官方标签和定义,包括附注(租赁、税务、回购、员工等)。
| 项目(SEC标签) | 最近季度 | 去年同期 | 同比 | 最近财年 | 上一财年 | 同比 |
|---|---|---|---|---|---|---|
| $89万 | $103万 | -13.5% | – | – | – | |
| Accounts Payable, Current | $7520万 | $3690万 | +103.8% | $3320万 | $3490万 | -5.1% |
| Accounts Receivable, after Allowance for Credit Loss, Current | $4.22亿 | $3.09亿 | +36.5% | $2.97亿 | $3.14亿 | -5.6% |
| Accounts Receivable, Allowance for Credit Loss | $802万2025-12-31 | $726万 | +10.5% | $802万 | $726万 | +10.5% |
| Accounts Receivable, Allowance for Credit Loss, Current | $653万 | $782万 | -16.6% | $802万 | $726万 | +10.5% |
| Accounts Receivable, Credit Loss Expense (Reversal) | – | – | – | $161万 | $128万 | +25.6% |
| Accrued Bonuses, Current | $4890万2025-12-31 | $3220万 | +51.8% | $4890万 | $3220万 | +51.8% |
| Accrued Insurance | $966万 | $970万 | -0.4% | $951万 | $1130万 | -15.7% |
| Accrued Marketing Costs, Current | $2620万 | $1660万 | +58.4% | $2020万 | $1650万 | +22.2% |
| Accrued Professional Fees | $5380万 | $8470万 | -36.5% | $5610万 | $5420万 | +3.4% |
| Accrued Sales Commission, Current | $1940万2025-12-31 | $1420万 | +36.5% | $1940万 | $1420万 | +36.5% |
| Accrued Vacation, Current | $470万2025-12-31 | $383万 | +22.8% | $470万 | $383万 | +22.8% |
| Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment | $1.33亿 | $9170万 | +45.5% | $1.11亿 | $7840万 | +41.7% |
| Accumulated Other Comprehensive Income (Loss), Net of Tax | -$10.8万 | -$28.7万 | +62.4% | -$25.8万 | -$34.4万 | +25.0% |
| Additional Paid in Capital, Common Stock | $47.5亿 | $39.8亿 | +19.3% | $44.9亿 | $37.6亿 | +19.3% |
| Advertising Expense | – | – | – | $1060万 | $230万 | +360.9% |
| Amortization of Debt Discount (Premium) | – | – | – | $99.1万2024-12-31 | $129万 | -23.3% |
| Amortization of Intangible Assets | $570万 | $0 | – | $390万 | $100万 | +290.0% |
| Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | -97.2万 | -55.3万 | -75.8% | 1250万 | 1450万 | -14.1% |
| APIC, Share-based Payment Arrangement, Increase for Cost Recognition | $1.02亿 | $9410万 | +8.4% | $3.57亿 | $2.77亿 | +29.1% |
| APIC, Share-based Payment Arrangement, Other, Increase for Cost Recognition | $0 | $81.2万 | -100.0% | $3290万 | $2410万 | +36.6% |
| Asset Impairment Charges | $0 | $0 | – | $02021-12-31 | – | – |
| Assets | $26.6亿 | $17.6亿 | +51.2% | $24亿 | $16.6亿 | +44.4% |
| Assets, Current | $16.6亿 | $14.3亿 | +15.9% | $15亿 | $13.8亿 | +8.8% |
| Assets, Fair Value Disclosure | $11.1亿 | – | – | – | – | – |
| Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability | -$557万 | $0 | – | – | – | – |
| Business Combination, Contingent Consideration, Liability | $1.21亿 | – | – | – | – | – |
| Business Combination, Contingent Consideration, Liability, Current | $2280万 | – | – | $2160万 | – | – |
| Business Combination, Contingent Consideration, Liability, Noncurrent | $9770万 | – | – | $9680万 | – | – |
| Capitalized Computer Software, Net | $3120万2025-12-31 | $1710万 | +82.5% | $3120万 | $1710万 | +82.5% |
| Cash and Cash Equivalents, Fair Value Disclosure | $10.9亿 | – | – | – | – | – |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | $10.9亿 | $10亿 | +9.1% | $10.8亿 | $9.46亿 | +13.8% |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect | $3470万2025-12-31 | $5270万 | -34.2% | $1.31亿 | $3.03亿 | -57.0% |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect | $357万 | $2630万 | -86.4% | – | – | – |
| Common Stock, Par or Stated Value Per Share | $0.00 | $0.00 | 0.0% | $0.00 | $0.00 | 0.0% |
| Common Stock, Shares Authorized | 7.5亿 | 7.5亿 | 0.0% | 7.5亿 | 7.5亿 | 0.0% |
| Common Stock, Shares, Issued | 1.44亿 | 1.37亿 | +5.0% | 1.4亿 | 1.33亿 | +5.3% |
| Common Stock, Shares, Outstanding | 1.44亿 | 1.37亿 | +5.0% | 1.4亿 | 1.33亿 | +5.3% |
| Common Stock, Value, Issued | $1.4万 | $1.4万 | 0.0% | $1.4万 | $1.2万 | +16.7% |
| Comprehensive Income (Loss), Net of Tax, Attributable to Parent | -$6690万 | -$1.01亿 | +33.8% | -$2.08亿 | -$1.88亿 | -10.9% |
| Contract with Customer, Liability | $5660万 | $3810万 | +48.8% | $4200万 | $3660万 | +14.7% |
| Contract with Customer, Liability, Change in Timeframe, Performance Obligation Satisfied, Revenue Recognized | -$1180万 | -$393万 | -200.6% | -$2590万 | -$2090万 | -23.8% |
| Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Change in Measure of Progress | -$1180万 | -$549万 | -114.5% | -$1920万 | -$1370万 | -40.2% |
| Contract with Customer, Liability, Current | $4060万 | $2160万 | +88.2% | $2490万 | $1980万 | +26.1% |
| Contract with Customer, Liability, Noncurrent | $1610万 | $1650万 | -2.5% | $1710万 | $1680万 | +1.3% |
| Costs and Expenses | $8.29亿 | $6.57亿 | +26.1% | $26.2亿 | $19.2亿 | +36.3% |
| Current Foreign Tax Expense (Benefit) | – | – | – | $20万 | – | – |
| Debt Conversion, Converted Instrument, Amount | – | – | – | $2.87亿2024-12-31 | – | – |
| Debt Instrument, Collateral Amount | $1.5亿 | $1.5亿 | 0.0% | $1.5亿 | $1.5亿 | 0.0% |
| Debt Securities, Available-for-sale | $10.9亿 | – | – | – | – | – |
| Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax | $0 | – | – | – | – | – |
| Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax | $0 | – | – | – | – | – |
| Debt Securities, Available-for-sale, Allowance for Credit Loss | $0 | $0 | – | $02024-12-31 | $0 | – |
| Debt Securities, Available-for-sale, Amortized Cost | $10.9亿 | – | – | – | – | – |
| Debt Securities, Available-for-sale, Current | $100万2025-09-30 | $2950万 | -96.6% | – | – | – |
| Debt Securities, Available-for-sale, Unrealized Loss Position | – | – | – | $1770万2024-12-31 | $1.15亿 | -84.7% |
| Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss | – | – | – | $33万2024-12-31 | $275万 | -88.0% |
| Debt Securities, Available-for-sale, Unrealized Loss Position, Number of Positions | – | – | – | 6 position2024-12-31 | 19 position | -68.4% |
| Deferred Federal Income Tax Expense (Benefit) | – | – | – | $5170万 | – | – |
| Deferred State and Local Income Tax Expense (Benefit) | – | – | – | $900万 | – | – |
来源:SEC companyfacts(每份10-Q / 10-K的XBRL)。现金流量表的季度数据由10-Q标记的年初至今累计数推算。分部拆分带有维度标记,在分部章节中单独展示。
数据来源
报表、分部营收、指标和预期均根据公司文件标准化。分部利润及全部披露项目:SEC EDGAR(XBRL)。 已读取的文件: 10-Q 2026-06-30, 10-Q 2026-03-31, 10-K 2025-12-31, 10-Q 2025-09-30, 10-Q 2025-06-30, 10-Q 2025-03-31, 10-K 2024-12-31, 10-Q 2024-09-30, 10-Q 2024-06-30
数据截至 2026-11-02